CLARITY MEDICAL (01406) achieved revenue of approximately HK$85 million in the first half of the 2026 fiscal year, a decrease of less than 3% compared to the same period last year.

CLARITY MEDICAL (01406) announced that as of the half-year financial period ending in 2026, the group has achieved revenue of approximately HKD 85 million, a slight decrease of less than 3% compared to the same period last year. Due to extremely adverse weather conditions, the group's clinics in Hong Kong were closed or severely disrupted for eight days from July to September. Additionally, negative media reports stemming from allegations made by a former director may have an adverse impact on the group's business in the past few months. The company has further solidified its leading position in the Hong Kong ophthalmology market by introducing the new generation refractive surgery technology SILK in exclusive partnership with Johnson & Johnson. This technology uses low-energy, ultra-precise femtosecond laser pulses to effectively reduce corneal tissue and nerve damage, leading to faster recovery and better postoperative results. As the first and only institution in Hong Kong to offer the SILK technology, the company plans to promote the technology in the fourth quarter of 2025.